Navigation Links
First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
Date:11/8/2011

San Francisco, CA November 8, 2011: Clinical researchers here reported the first results of a pilot study with the anticoagulant Angiomax (bivalirudin) as an adjunct to catheter-based procedures in patients with severely defective aortic heart valves in whom surgery was not possible. The results showed a 60% reduction in major bleeding events (from 13% to 5%, p = 0.003) in patients treated with Angiomax compared to patients treated with heparin. This investigational use of Angiomax is not approved in these procedures, collectively known as transcatheter aortic valve interventions. Angiomax is approved for patients undergoing percutaneous coronary interventions (PCI) with provisional glycoprotein IIb/IIIa inhibitor (GPI).

George D. Dangas, MD, PhD, of Mount Sinai Medical Center New York, NY led this study, which was also conducted at the University of Miami Health System (Drs. Annapoorna S. Kini and Mauricio Cohen were the respective team leaders) in a program called BRAVO (BivaliRudin to improve Aortic Valve intervention Outcomes), which is sponsored by The Medicines Company (NASDAQ: MDCO). The data were reported here at the Cardiovascular Research Foundation (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

The data reported by Dr. Dangas were the results from a two-center retrospective registry of 428 patients with severe aortic stenosis undergoing balloon valvuloplasty (BAV) via transfemoral access and the use of bivalirudin. BAV involves the insertion of a compressed balloon into a catheter, a long, thin, tube-like device. The catheter and balloon are inserted into the femoral artery through a small cut in the leg and threaded to the site of the diseased valve. The balloon is then inflated in an effort to increase the opening size of the valve and improve blood flow.

The study met its two objectives, demonstrating patients treated with bivalirudin versus unfractionated heparin experienced:

  • Reduced rates of in-hospital major bleeding
  • Reduced rates of in-hospital net adverse clinical events (major bleeding, all-cause mortality, myocardial infarction or stroke)

Dr. Dangas noted, "Technologies to enable heart valve replacement or repair without cracking open a patient's chest are emerging rapidly. Last week's US approval of the SapienTM valve is the most recent example."

Anticoagulants are needed peri-procedurally to prevent clotting on the treated area and clotting in other organs such as the brain, which can result in a stroke; however, anticoagulants carry a risk of vascular and bleeding complications. Dr. Dangas said, "Advances in procedures such as PCI, valvuloplasty and TAVI may require improvements in anticoagulation to yield improved patient outcomes."

Clive Meanwell, MD, PhD, Chairman and Chief Executive Officer of The Medicines Company said, "These results validate the commitment we made to study Angiomax once our patent rights were supported. I look forward to seeing the BRAVO program move ahead with a planned study in more patients next year. With continued certainty, we will be positioned to explore the potential of Angiomax to deliver clinical and economic advantages in other uses."


'/>"/>

Contact: Rebecca Hollins
rebecca.hollins@themedco.com
973-290-6081
The Medicines Company
Source:Eurekalert

Related medicine news :

1. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
2. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
3. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
4. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
5. MSU launches first anti-counterfeiting research program
6. AMA Joins First Lady in Fight Against Childhood Obesity
7. National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
10. First Gene Variants Linked to Stuttering Discovered
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... VA (PRWEB) , ... March ... ... Evaluation Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. ... 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life ... infinitely more profound faith of God’s promise of Heaven for His people. “My Journey ... each day with his wife, three children and six grandchildren living and doing for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") ... is pleased to announce that its majority-owned subsidiary, ... U.S. Food and Drug Administration (FDA) for the ... tablets in the 12.5 mg and 25 mg ... equivalent of the branded product Xenazine ® ...
(Date:3/23/2017)... , March 23, 2017 ReNeuron ... its CTX cells in chronic stroke patients, despite not meeting ... primary outcome measure, the Action Research Arm Test (ARAT). As ... to a pivotal controlled clinical study in 2017. Beyond CTX, ... (RP) trial in 2017 and Phase I data from its ...
(Date:3/23/2017)... 2017 The Board of Directors of NeuroVive ... Meeting, which is to take place on Thursday, April 27, 2017, ... Lund, Sweden . ... Please see the attached notification, which is being announced within ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors About ...
Breaking Medicine Technology: